Biohaven’s Q3 Nurtec ODT Sales Indicate Gains Across Multiple Launch Parameters
Growth Seen In First Full Quarter With Dual Migraine Indications
The company pre-announced $136m in third quarter sales, beating analyst consensus and signaling both increased oral CGRP inhibitor market share and improved per-prescription net revenue.
